Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fluzoparib with Rifampicin in Healthy Males
NCT04011124Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in ovarian cancer, sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration of Fluzoparib and Area Under the Plasma Concentration versus Time Curve of Fluzoparib. Started Jul 2019; status: completed.
02
Drugs
fluzoparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04011124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04011124.